Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.

Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2009 Jul;16(7):551-60. doi: 10.1038/cgt.2009.10. Epub 2009 Feb 6.

PMID:
19197321
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
[PubMed - indexed for MEDLINE]
3.

An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.

Zeng WG, Li JJ, Hu P, Lei L, Wang JN, Liu RB.

Oncol Rep. 2013 Jun;29(6):2355-61. doi: 10.3892/or.2013.2359. Epub 2013 Mar 22.

PMID:
23525624
[PubMed - indexed for MEDLINE]
4.

Oncolytic herpes simplex virus treatment of metastatic breast cancer.

Wang J, Hu P, Zeng M, Rabkin SD, Liu R.

Int J Oncol. 2012 Mar;40(3):757-63. doi: 10.3892/ijo.2011.1266. Epub 2011 Nov 21.

PMID:
22108767
[PubMed - indexed for MEDLINE]
5.

Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.

Clin Cancer Res. 2006 Nov 15;12(22):6791-9.

PMID:
17121900
[PubMed - indexed for MEDLINE]
Free Article
6.

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL.

Cancer Gene Ther. 2006 Mar;13(3):253-65.

PMID:
16179929
[PubMed - indexed for MEDLINE]
7.

Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.

Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, Pikarsky E, Rabkin SD, Panet A, Zamir G.

Gene Ther. 2009 Jul;16(7):905-15. doi: 10.1038/gt.2009.44. Epub 2009 May 14.

PMID:
19440231
[PubMed - indexed for MEDLINE]
8.

Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.

Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Halldén G.

Hum Gene Ther. 2010 Oct;21(10):1311-25. doi: 10.1089/hum.2010.019.

PMID:
20497039
[PubMed - indexed for MEDLINE]
9.

Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.

Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL.

Gene Ther. 2009 Dec;16(12):1477-82. doi: 10.1038/gt.2009.94. Epub .

PMID:
19693098
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.

Lee CY, Rennie PS, Jia WW.

Clin Cancer Res. 2009 Aug 15;15(16):5126-35. doi: 10.1158/1078-0432.CCR-09-0051. Epub 2009 Aug 11.

PMID:
19671871
[PubMed - indexed for MEDLINE]
Free Article
11.

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A.

Mol Ther. 2006 Dec;14(6):789-97. Epub 2006 Oct 10.

PMID:
17045531
[PubMed - indexed for MEDLINE]
12.
13.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL.

J Natl Cancer Inst. 2012 Jan 4;104(1):42-55. doi: 10.1093/jnci/djr509. Epub 2011 Dec 15.

PMID:
22173583
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Todo T, Martuza RL, Rabkin SD, Johnson PA.

Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401. Epub 2001 May 15.

PMID:
11353831
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.

Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T.

Clin Cancer Res. 2005 Nov 1;11(21):7886-90.

PMID:
16278413
[PubMed - indexed for MEDLINE]
Free Article
16.

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS.

BMC Cancer. 2011 Jun 6;11:221. doi: 10.1186/1471-2407-11-221.

PMID:
21645351
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F.

Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14.

PMID:
19604626
[PubMed - indexed for MEDLINE]
18.

Active immunotherapy: oncolytic virus therapy using HSV-1.

Todo T.

Adv Exp Med Biol. 2012;746:178-86. doi: 10.1007/978-1-4614-3146-6_14. Review.

PMID:
22639168
[PubMed - indexed for MEDLINE]
19.

Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.

Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2013 Jan;20(1):17-24. doi: 10.1038/cgt.2012.75. Epub 2012 Nov 9.

PMID:
23138870
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk